What stands out
- Most companies in its industry are production businesses; this one is a sense-making business
At a glance
- Depends onUpstream position: supplies 6 industries, depends on 3
- ScaleMarket cap is $2.02B, above the global median of $1.15B
- FinancialsAltman Z-Score 12.48: safe zone
What this company is and how it runs — written from structure, not news.
What stands out
- Most companies in its industry are production businesses; this one is a sense-making business
Sign in to view price data.
Sign inThe reported statements, read against the company's own industry.
Financials view
Market Capitalization
13.60BCNY2.02B · vs all stocks (USD)
Revenue (TTM)
1.26BCNY187.47M · vs all stocks (USD)
Profit Margin
-10.92%vs Biotechnology peers
Beta
0.7110xvs all stocks
52-Week Change
61.79%vs all stocks
Market Capitalization
13.60BCNY2.02B · vs all stocks (USD)
Enterprise Value
14.04BCNY2.09B · vs all stocks (USD)
Forward P/E
49.77xvs Biotechnology peers
Price to Sales (TTM)
11.72xvs Biotechnology peers
Price to Book (MRQ)
7.31xvs Biotechnology peers
Enterprise to Revenue
11.13xvs Biotechnology peers
Gross Margin
26.06%vs Biotechnology peers
Profit Margin
-10.92%vs Biotechnology peers
Operating Margin
3.95%vs Biotechnology peers
Return on Assets (TTM)
-3.45%vs Biotechnology peers
Return on Equity (TTM)
-6.74%vs Biotechnology peers
Revenue (TTM)
1.26BCNY187.47M · vs all stocks (USD)
Revenue per Share (TTM)
9.58CNYUpdated Aug 21, 2026Quarterly Revenue Growth
36.50%vs Biotechnology peers
Gross Profit (TTM)
228.69MCNY34.01M · vs all stocks (USD)
EBITDA (TTM)
10.87MCNY1.62M · vs all stocks (USD)
Net Income (TTM)
-137.67MCNY-20.47M · vs all stocks (USD)
Quarterly Earnings Growth (YoY)
54.50%vs Biotechnology peers
Operating Cash Flow (TTM)
99.40MCNY14.78M · vs all stocks (USD)
Levered Free Cash Flow (TTM)
113.98MCNY16.95M · vs all stocks (USD)
Payout Ratio
0.00%vs Biotechnology peers
Revenue
1.16BCNYFY2025 · Dec 31, 2025Cost of Goods Sold
961.18MCNYFY2025 · Dec 31, 2025Gross Profit
201.88MCNYFY2025 · Dec 31, 2025Operating Income
-97.75MCNY-14.54M · vs all stocks (USD)
Pre-tax Income
-185.00MCNYFY2025 · Dec 31, 2025Income Tax Expense
-17.17MCNYFY2025 · Dec 31, 2025Net Income
-167.83MCNYFY2025 · Dec 31, 2025EBIT
-175.49MCNYFY2025 · Dec 31, 2025EBITDA (Income Statement)
10.87MCNYFY2025 · Dec 31, 2025Research & Development
104.41MCNYFY2025 · Dec 31, 2025Selling, General & Administrative
76.40MCNYFY2025 · Dec 31, 2025Other Operating Expenses
3.18MCNYFY2025 · Dec 31, 2025Non-operating Interest Income
4.51MCNYFY2025 · Dec 31, 2025Non-operating Interest Expense
9.51MCNYFY2025 · Dec 31, 2025EPS (Basic)
-1.27CNYFY2025 · Dec 31, 2025EPS (Diluted)
-1.27CNYFY2025 · Dec 31, 2025Basic Shares Outstanding
132.15MSharesFY2025 · Dec 31, 2025Diluted Shares Outstanding
132.15MSharesFY2025 · Dec 31, 2025Net Income from Continuing Operations
-167.83MCNYFY2025 · Dec 31, 2025Preferred Stock Dividends
0.00CNYFY2025 · Dec 31, 2025Operating Cash Flow
-133.22MCNYFY2025 · Dec 31, 2025Free Cash Flow
-202.18MCNYFY2025 · Dec 31, 2025Cash & Cash Equivalents (End of Period)
249.73MCNYFY2025 · Dec 31, 2025Starting Profit (CF Statement)
-167.83MCNYFY2025 · Dec 31, 2025Other Non-cash Items
42.29MCNYFY2025 · Dec 31, 2025Change in Accounts Receivable (CF)
25.13MCNYFY2025 · Dec 31, 2025Change in Other Assets/Liabilities
-32.80MCNYFY2025 · Dec 31, 2025Capital Expenditures
-68.96MCNYFY2025 · Dec 31, 2025Purchase of Investments
-1.12BCNYFY2025 · Dec 31, 2025Sale of Investments
1.26BCNYFY2025 · Dec 31, 2025Other Investing Activity
-295.99KCNYFY2025 · Dec 31, 2025Net Investing Cash Flow
74.56MCNYFY2025 · Dec 31, 2025Long-term Debt Issuance
360.08MCNYFY2025 · Dec 31, 2025Long-term Debt Payments
-493.50MCNYFY2025 · Dec 31, 2025Common Dividends Paid
-7.42MCNYFY2025 · Dec 31, 2025Other Financing Charges
-45.13MCNYFY2025 · Dec 31, 2025Net Financing Cash Flow
-185.97MCNYFY2025 · Dec 31, 2025Shares Outstanding
134.35MSharesUpdated Aug 21, 2026Float Shares
73.92MSharesUpdated Aug 21, 2026% Held by Insiders
41.22%vs all stocks
% Held by Institutions
9.34%vs all stocks
Total Cash (MRQ)
564.81MCNY83.99M · vs all stocks (USD)
Total Cash per Share (MRQ)
4.34CNYUpdated Aug 21, 2026Total Debt (MRQ)
287.46MCNY42.75M · vs all stocks (USD)
Total Debt to Equity (MRQ)
0.1468xvs Biotechnology peers
Current Ratio (MRQ)
1.93xvs Biotechnology peers
Book Value per Share (MRQ)
15.05CNYUpdated Aug 21, 2026Total Assets
2.62BCNY389.93M · vs all stocks (USD)
Total Current Assets
1.22BCNYFY2025 · Dec 31, 2025Total Liabilities
687.85MCNYFY2025 · Dec 31, 2025Total Non-current Assets
1.40BCNYFY2025 · Dec 31, 2025Total Non-current Liabilities
110.38MCNYFY2025 · Dec 31, 2025Total Current Liabilities
577.48MCNYFY2025 · Dec 31, 2025Cash
249.72MCNYFY2025 · Dec 31, 2025Cash Equivalents
37.06MCNYFY2025 · Dec 31, 2025Cash & Cash Equivalents
286.78MCNYFY2025 · Dec 31, 2025Other Short-term Investments
113.41MCNYFY2025 · Dec 31, 2025Accounts Receivable
408.31MCNYFY2025 · Dec 31, 2025Inventory
112.22MCNYFY2025 · Dec 31, 2025Accounts Payable
175.80MCNYFY2025 · Dec 31, 2025Short-term Debt
192.87MCNYFY2025 · Dec 31, 2025Other Current Liabilities
3.16MCNYFY2025 · Dec 31, 2025Long-term Debt
54.56MCNYFY2025 · Dec 31, 2025Other Non-current Liabilities
7.09MCNYFY2025 · Dec 31, 2025Common Stock (Book)
134.35MCNYFY2025 · Dec 31, 2025Retained Earnings
191.71MCNYFY2025 · Dec 31, 2025Total Shareholders' Equity
1.93BCNY287.64M · vs all stocks (USD)
Treasury Stock
64.01MCNYFY2025 · Dec 31, 202552-Week Low
50.50CNYUpdated Aug 21, 202652-Week High
113.60CNYUpdated Aug 21, 202652-Week Change
61.79%vs all stocks
Beta
0.7110xvs all stocks
50-Day MA
78.95CNYUpdated Aug 21, 2026200-Day MA
66.76CNYUpdated Aug 21, 2026Avg 10-Day Volume
11.82MSharesUpdated Aug 21, 2026Avg 30-Day Volume
10.18MSharesUpdated Aug 21, 2026Diluted EPS (TTM)
-1.04CNYUpdated Aug 21, 2026Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Structural Tensions
Most companies in its industry are production businesses; this one is a sense-making businessSignificant
Industry peers: 502Share on the common pattern %: 98.00
Financial Health
Altman Z-Score 12.48: safe zoneNotable
Altman Z-Score: 12.48
Supply Chain
Upstream position: supplies 6 industries, depends on 3Notable
Outgoing: 6.00Incoming: 3.00
Scale
Market cap is $2.02B, above the global median of $1.15BNotable
Market cap (USD): 2,021,926,744.084Global Median: 1,146,734,693.424
Levered free cash flow is $16.95M, above the global median of $16.24MNotable
Levered free cash flow (USD): 16,949,827.797Global Median: 16,239,329.704
Companies that share the same coordination system — how they create, deliver, or capture value.
Caris Life Sciences, Inc.
Tier 1SenseMakingApproval-Gated PipelineProductionInterface
Evotec SE
Tier 1SenseMakingApproval-Gated PipelineInterfaceProduction
Hvivo Plc
Tier 1SenseMakingApproval-Gated PipelineProductionRule
Ixico plc
Tier 1SenseMakingApproval-Gated PipelineProductionInterface
Fusion Antibodies Ltd.
Tier 1SenseMakingApproval-Gated PipelineProduction
Fortrea Holdings Inc.
Tier 2SenseMakingApproval-Gated PipelineFlowInterface
Planisware SA
Tier 3SenseMakingRecurring-Revenue Lock-InProductionInterface
Innodata Inc.
Tier 3SenseMakingExpertise LeverageProductionFlow
Perdoceo Education Corporation
Tier 3SenseMakingExpertise LeverageProductionRule
Offcn Education Technology Co. Ltd.
Tier 3SenseMakingExpertise LeverageProductionInterface